Role of transforming growth factor-β1 −509 C/T promoter polymorphism in gastric cancer in south Indian population
- 121 Downloads
Gastric cancer is a multifactorial disease with the involvement of both genetic and environmental risk factors. Genetic variation in genes encoding cytokines and their receptors determine the intensity of the inflammatory response, which may contribute to individual differences in the outcome and severity of the disease. Transforming growth factor (TGF-β) signaling pathway plays an important role in the genesis and progression of tumors through regulating cell proliferation and differentiation. A hospital-based case–control study was conducted to investigate whether TGF-β1 −509 C/T polymorphism can modify the risk of gastric cancer. Seventy endoscopically and histopathologically confirmed gastric cancer patients and 100 age and sex-matched healthy controls were enrolled in the case–control study. TGF-β1 −509 C/T gene polymorphism was carried out by amplification refractory mutation system polymerase chain reaction (ARMS-PCR) method followed by agarose gel electrophoresis. Statistical analysis was applied to test for the significance of the results. The distribution of TGF-β1 genotypes at −509 C/T were CC 37.14%, CT 50%, and TT 12.86% in gastric cancer patients and CC 52%, CT 42%, and TT 6% in control subjects. The allelic frequencies of C and T were 0.621 and 0.379 in gastric cancer patients and 0.73 and 0.27 in control subjects, respectively. Our study imply that T allele of TGF-β1 −509 C/T genotypes may be a risk factor of genetic susceptibility to gastric cancer in south Indian population.
KeywordsTransforming growth factor β1 Gastric cancer Polymorphism Cytokine
Financial support from Council for Scientific and Industrial Research (CSIR) is kindly acknowledged.
Conflict of interest
The authors declare that they have no conflict of interest.
- 1.Cancer (Fact sheet N297). World Health Organization. February 2009 http://www.who.int/mediacentre/factsheets/fs297/en/. Accessed on 24March 2011.
- 8.Saito H, Tsujitani S, Oka S, Kondo A, Ikeguchi M, Maeta M, et al. An elevated serum level of transforming growth factor-beta 1 (TGF-beta 1) significantly correlated with lymph node metastasis and poor prognosis in patients with gastric carcinoma. Anticancer Res. 2000;20(6B):4489–93.PubMedGoogle Scholar
- 23.Dunning AM, Ellis PD, McBride S, Kirschenlohr HL, Healey CS, Kemp PR, et al. A transforming growth factor beta1 signal peptide variant increases secretion in vitro and is associated with increased incidence of invasive breast cancer. Canc Res. 2003;63(10):2610–5.Google Scholar